Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
The Ras Gene02:38

The Ras Gene

6.4K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.4K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

6.1K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.

British journal of haematology·2026
Same author

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

American journal of hematology·2026
Same author

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL.

Blood advances·2026
Same author

CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study.

Cancer research communications·2026
Same author

Therapeutic Targeting of IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation in Juvenile Myelomonocytic Leukemia.

Blood·2026
Same author

Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.

Leukemia·2026

相关实验视频

Updated: Sep 15, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K

多选择性RAS ((ON) 抑制向瘤性RAS突变并克服RAS/MAPK介导的FLT3和BCL2抑制剂对急性髓性白血病的抗性.

Bogdan Popescu1, Matthew F Jones1, Madison Piao1

  • 1Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.

bioRxiv : the preprint server for biology
|July 15, 2025
PubMed
概括

一种新型药物RMC-7977针对急性髓性白血病 (AML) 的RAS激活. 这种RAS抑制剂克服了对FLT3抑制剂和venetoclax的耐药性,显示出AML治疗的希望.

更多相关视频

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

276

相关实验视频

Last Updated: Sep 15, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

276

科学领域:

  • 血液学 血液学 血液学
  • 在瘤学瘤学.
  • 分子生物学分子生物学

背景情况:

  • 异常的RAS/MAPK信号驱动了急性髓性白血病 (AML) 针对性治疗的耐药性.
  • 在AML中,RAS突变赋予FLT3抑制剂 (FLT3i) 和venetoclax的耐药性.
  • 准RAS/MAPK信号对于提高AML治疗疗效至关重要.

研究的目的:

  • 为了研究RMC-7977的临床前疗效,RMC-7977是一种新型的活性RAS(ON) 异型的抑制剂.
  • 评估RMC-7977在AML模型中克服FLT3i和venetoclax耐药性的能力.
  • 评估RMC-7977与现有的AML疗法结合使用的安全性和有效性.

主要方法:

  • 在AML细胞系具有MAPK激活突变的RMC-7977的临床前评估.
  • 评估RMC-7977对耐药AML模型 (FLT3i耐药和venetoclax耐药) 的影响.
  • 在活体研究中,使用来自小鼠患者的RAS突变AML的异种移植模型.

主要成果:

  • RMC-7977在AML细胞系中表现出强烈的抗增殖和亲细胞亡活性.
  • 在获得RAS介导抗性的模型中,RMC-7977恢复了对FLT3i的敏感性.
  • 在RAS成的AML模型中,RMC-7977逆转了venetoclax耐药性.
  • 用RMC-7977和吉尔特里尼布或维内托克拉克斯的联合治疗在体内抑制了白血病负担.

结论:

  • RMC-7977对RAS驱动的AML具有显著的临床前活性.
  • 广谱RAS (ON) 抑制是克服AML药物耐药性的有希望的策略.
  • 在AML治疗中,需要对RMC-7977进行临床研究.